Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, China (mainland).
Department of Medical Oncology, Suixi County Hospital, Huaibei, Anhui, China (mainland).
Med Sci Monit. 2018 Jan 18;24:348-355. doi: 10.12659/msm.908447.
BACKGROUND The aim of this study was to investigate the expression level of martrilin-3 (MATN3) in patients with gastric adenocarcinoma (GAC) and to investigate the prognostic significance of MATN3. MATERIAL AND METHODS Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data were used to predict the expression and prognostic value of MATN3 mRNA in GAC patients. Seventy-six GAC patients had GAC tissue samples and paired adjacent normal tissue samples collected retrospectively to examine the MATN3 protein expression level by immunohistochemical staining. Furthermore, Kaplan-Meier univariate and Cox multivariate analyses were used to verify the correlation between MATN3 expression and clinicopathological parameters of GAC patients and the prognostic significance of MATN3. RESULTS The GEO and TCGA data predicted that MATN3 mRNA levels were significantly higher in GAC tissue compared to normal tissue (all p<0.05). Further survival analyses showed that GAC patients with high mRNA expression of MATN3 had significantly lower disease-free survival (DFS) and overall survival (OS) time than those with low mRNA expression of MATN3 (all p<0.05). Subsequent immunohistochemical staining results confirmed that the MATN3 protein levels in GAC tissues were highly expressed (p=0.000) compared to normal tissues. In addition, GAC patients with high protein expression of MATN3 had remarkably decreased OS compared to patients with low protein expression of MATN3 (p=0.000). Univariate and multivariate survival analyses revealed that MATN3 high expression could be used as an independent predictor of poor prognosis in GAC patients (all p=0.000). CONCLUSIONS This study confirmed that MATN3 protein was highly expressed in GAC patients, and MATN3 overexpression could be used as an independent predictor of poor prognosis in GAC patients.
本研究旨在探讨胃腺癌(GAC)患者中 martrilin-3(MATN3)的表达水平,并探讨 MATN3 的预后意义。
使用基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)数据来预测 GAC 患者中 MATN3 mRNA 的表达和预后价值。回顾性收集了 76 例 GAC 患者的 GAC 组织样本和配对的相邻正常组织样本,通过免疫组织化学染色来检测 MATN3 蛋白的表达水平。此外,采用 Kaplan-Meier 单因素和 Cox 多因素分析来验证 MATN3 表达与 GAC 患者临床病理参数的相关性及其对 GAC 患者预后的意义。
GEO 和 TCGA 数据预测,与正常组织相比,GAC 组织中 MATN3 mRNA 水平显著升高(均 p<0.05)。进一步的生存分析表明,MATN3 mRNA 高表达的 GAC 患者无病生存(DFS)和总生存(OS)时间明显短于 MATN3 mRNA 低表达的患者(均 p<0.05)。随后的免疫组织化学染色结果证实,GAC 组织中 MATN3 蛋白水平高度表达(p=0.000),明显高于正常组织。此外,MATN3 蛋白高表达的 GAC 患者的 OS 明显低于 MATN3 蛋白低表达的患者(p=0.000)。单因素和多因素生存分析表明,MATN3 高表达可作为 GAC 患者预后不良的独立预测因子(均 p=0.000)。
本研究证实,MATN3 蛋白在 GAC 患者中高度表达,MATN3 过表达可作为 GAC 患者预后不良的独立预测因子。